Top segments and regional performance

Last year, the company generated ‪9.01 M‬ EUR, the most of which — ‪9.01 M‬ EUR — came from its top-performing segment, Research and Development of Pharmaceutical Products, compared to ‪20.12 M‬ EUR the previous year. The greatest contribution came from France, which accounted for ‪9.01 M‬ EUR last year, with ‪20.12 M‬ EUR the year before.